458 related articles for article (PubMed ID: 33648515)
1. Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study.
Gaborit B; Ancel P; Abdullah AE; Maurice F; Abdesselam I; Calen A; Soghomonian A; Houssays M; Varlet I; Eisinger M; Lasbleiz A; Peiretti F; Bornet CE; Lefur Y; Pini L; Rapacchi S; Bernard M; Resseguier N; Darmon P; Kober F; Dutour A
Cardiovasc Diabetol; 2021 Mar; 20(1):57. PubMed ID: 33648515
[TBL] [Abstract][Full Text] [Related]
2. Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial.
Kahl S; Gancheva S; Straßburger K; Herder C; Machann J; Katsuyama H; Kabisch S; Henkel E; Kopf S; Lagerpusch M; Kantartzis K; Kupriyanova Y; Markgraf D; van Gemert T; Knebel B; Wolkersdorfer MF; Kuss O; Hwang JH; Bornstein SR; Kasperk C; Stefan N; Pfeiffer A; Birkenfeld AL; Roden M
Diabetes Care; 2020 Feb; 43(2):298-305. PubMed ID: 31540903
[TBL] [Abstract][Full Text] [Related]
3. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study.
Hiruma S; Shigiyama F; Hisatake S; Mizumura S; Shiraga N; Hori M; Ikeda T; Hirose T; Kumashiro N
Cardiovasc Diabetol; 2021 Feb; 20(1):32. PubMed ID: 33530982
[TBL] [Abstract][Full Text] [Related]
4. Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes.
Sarak B; Verma S; David Mazer C; Teoh H; Quan A; Gilbert RE; Goodman SG; Bami K; Coelho-Filho OR; Ahooja V; Deva DP; Garg V; Gandhi S; Connelly KA; Yan AT
Cardiovasc Diabetol; 2021 Oct; 20(1):200. PubMed ID: 34607574
[TBL] [Abstract][Full Text] [Related]
5. Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial.
McGuire DK; Zinman B; Inzucchi SE; Wanner C; Fitchett D; Anker SD; Pocock S; Kaspers S; George JT; von Eynatten M; Johansen OE; Jamal W; Mattheus M; Elsasser U; Hantel S; Lund SS
Lancet Diabetes Endocrinol; 2020 Dec; 8(12):949-959. PubMed ID: 33217335
[TBL] [Abstract][Full Text] [Related]
6. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
Verma S; Mazer CD; Yan AT; Mason T; Garg V; Teoh H; Zuo F; Quan A; Farkouh ME; Fitchett DH; Goodman SG; Goldenberg RM; Al-Omran M; Gilbert RE; Bhatt DL; Leiter LA; Jüni P; Zinman B; Connelly KA
Circulation; 2019 Nov; 140(21):1693-1702. PubMed ID: 31434508
[TBL] [Abstract][Full Text] [Related]
7. Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the "Cardiac Benefits" of Empagliflozin Independent of its Hypoglycemic Activity?
Santos-Gallego CG; Garcia-Ropero A; Mancini D; Pinney SP; Contreras JP; Fergus I; Abascal V; Moreno P; Atallah-Lajam F; Tamler R; Lala A; Sanz J; Fuster V; Badimon JJ
Cardiovasc Drugs Ther; 2019 Feb; 33(1):87-95. PubMed ID: 30675708
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin.
Tanaka A; Shimabukuro M; Teragawa H; Okada Y; Takamura T; Taguchi I; Toyoda S; Tomiyama H; Ueda S; Higashi Y; Node K;
Cardiovasc Diabetol; 2021 Jul; 20(1):160. PubMed ID: 34332584
[TBL] [Abstract][Full Text] [Related]
9. Can we go beyond surrogates?
Drexler A
J Diabetes; 2017 Nov; 9(11):976-977. PubMed ID: 28692750
[TBL] [Abstract][Full Text] [Related]
10. Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial.
Ceriello A; Ofstad AP; Zwiener I; Kaspers S; George J; Nicolucci A
Cardiovasc Diabetol; 2020 Oct; 19(1):176. PubMed ID: 33050931
[TBL] [Abstract][Full Text] [Related]
11. Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial.
Sattar N; Fitchett D; Hantel S; George JT; Zinman B
Diabetologia; 2018 Oct; 61(10):2155-2163. PubMed ID: 30066148
[TBL] [Abstract][Full Text] [Related]
12. Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial.
Bonora BM; Vigili de Kreutzenberg S; Avogaro A; Fadini GP
Cardiovasc Diabetol; 2019 Aug; 18(1):106. PubMed ID: 31412874
[TBL] [Abstract][Full Text] [Related]
13. Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study.
Rau M; Thiele K; Hartmann NK; Schuh A; Altiok E; Möllmann J; Keszei AP; Böhm M; Marx N; Lehrke M
Cardiovasc Diabetol; 2021 Jan; 20(1):6. PubMed ID: 33413355
[TBL] [Abstract][Full Text] [Related]
14. Study rationale and design of a study of EMPAgliflozin's effects in patients with type 2 diabetes mellitus and Coronary ARtery disease: the EMPA-CARD randomized controlled trial.
Gohari S; Reshadmanesh T; Khodabandehloo H; Fathi M; Ahangar H; Arsang-Jang S; Ismail-Beigi F; Ghanbari S; Dadashi M; Muhammadi MJ; Gohari S; Ghaffari S
BMC Cardiovasc Disord; 2021 Jun; 21(1):318. PubMed ID: 34193056
[TBL] [Abstract][Full Text] [Related]
15. Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium-glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes.
Yabe D; Shiki K; Suzaki K; Meinicke T; Kotobuki Y; Nishida K; Clark D; Yasui A; Seino Y
BMJ Open; 2021 Apr; 11(4):e045844. PubMed ID: 33827843
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
Fuchigami A; Shigiyama F; Kitazawa T; Okada Y; Ichijo T; Higa M; Hiyoshi T; Inoue I; Iso K; Yoshii H; Hirose T; Kumashiro N
Cardiovasc Diabetol; 2020 Jan; 19(1):1. PubMed ID: 31910850
[TBL] [Abstract][Full Text] [Related]
17. Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers.
Gessner A; Gemeinhardt A; Bosch A; Kannenkeril D; Staerk C; Mayr A; Fromm MF; Schmieder RE; Maas R
Cardiovasc Diabetol; 2022 Jan; 21(1):4. PubMed ID: 34991562
[TBL] [Abstract][Full Text] [Related]
18. Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus.
Lai LL; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
Dig Dis Sci; 2020 Feb; 65(2):623-631. PubMed ID: 30684076
[TBL] [Abstract][Full Text] [Related]
19. Compensatory changes in energy balance during dapagliflozin treatment in type 2 diabetes mellitus: a randomised double-blind, placebo-controlled, cross-over trial (ENERGIZE)-study protocol.
Rajeev SP; Sprung VS; Roberts C; Harrold JA; Halford JC; Stancak A; Boyland EJ; Kemp GJ; Cuthbertson DJ; Wilding JP
BMJ Open; 2017 Jan; 7(1):e013539. PubMed ID: 28132008
[TBL] [Abstract][Full Text] [Related]
20. The effect of dapagliflozin treatment on epicardial adipose tissue volume.
Sato T; Aizawa Y; Yuasa S; Kishi S; Fuse K; Fujita S; Ikeda Y; Kitazawa H; Takahashi M; Sato M; Okabe M
Cardiovasc Diabetol; 2018 Jan; 17(1):6. PubMed ID: 29301516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
